BHC
Bausch Health Companies Inc.
BHC has slightly lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over BHC overall, supported by stronger fundamentals.
BHC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Strong | |
| Weak |
BHC's revenue and cash flow are currently healthy, but its profitability and balance sheet are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
BHC PE Valuation
BHC has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
BHC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Stable | |
| Stable | |
| Limited | |
| High |
Analysts expect BHC's earnings, revenue and profitability to hold roughly steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over BHC on the outlook, with more favorable earnings and revenue expectations.
BHC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.30 | — |
| Q3 2026 | -$2.29 | -339% |
| Q2 2026 | -$2.96 | -1284% |
| Q1 2026 | -$3.24 | -$3.12 |
| Q4 2025 | $0.42 | +$0.55 |
| Q3 2025 | $0.96 | +$1.44 |
| Q2 2025 | $0.25 | +$1.53 |
| Q1 2025 | -$0.12 | +$1.12 |
| Q4 2024 | -$0.13 | +$1.49 |
BHC has swung to a loss: it lost $2.29 per share over the past year, after a profit the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over BHC on earnings quality, reporting a profit while its opponent remains loss making.
BHC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.9B | +9.7% |
| Q2 2026 | $2.9B | +13% |
| Q1 2026 | $2.5B | +12% |
| Q4 2025 | $2.8B | +9.3% |
| Q3 2025 | $2.7B | +6.8% |
| Q2 2025 | $2.5B | +5.3% |
| Q1 2025 | $2.3B | +4.9% |
| Q4 2024 | $2.6B | +6.3% |
BHC's revenue has grown year over year for 15 quarters in a row: $2.9B last quarter, up 9.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 33% | +10 points |
| Q2 2026 | 26% | +8.4 points |
| Q1 2026 | -38% | -50 points |
| Q4 2025 | 17% | -4.9 points |
| Q3 2025 | 23% | +10 points |
| Q2 2025 | 18% | +1.4 points |
| Q1 2025 | 12% | -0.8 points |
| Q4 2024 | 22% | +6.8 points |
BHC has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over BHC on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
BHC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $748M | +138% |
| Q2 2026 | $593M | +212% |
| Q1 2026 | $121M | +26% |
| Q4 2025 | $403M | -19% |
| Q3 2025 | $314M | -6% |
| Q2 2025 | $190M | -37% |
| Q1 2025 | $96M | -26% |
| Q4 2024 | $495M | +70% |
BHC generated $1.9B in free cash flow over the past year, up 70% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over BHC on cash flow, with more consistent year-over-year improvement.
BHC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +2.6M shares |
| 1 year | +1.4% | +5.2M shares |
| 3 years | +4.2% | +15.3M shares |
| 5 years | +4.6% | +16.7M shares |
| Available history | +8.1% | +28.6M shares |
BHC has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
BHC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.6x | High |
| Q2 2026 | 9.2x | High |
| Q1 2026 | 10.9x | High |
| Q4 2025 | 6.5x | High |
| Q3 2025 | 6.3x | High |
| Q2 2025 | 7.1x | High |
| Q1 2025 | 7.3x | High |
| Q4 2024 | 7.3x | High |
BHC's net debt is about 7.6 years of its operating earnings (EBITDA), up from 6.3 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over BHC on leverage, with a lower net debt burden relative to earnings.
BHC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 71.2 | Overbought |
| Stochastic | 78.2 | Neutral |
BHC's weekly RSI is 71 (overbought) and its Stochastic is 78 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
BHC PE vs Healthcare Sector
| Metric | BHC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
BHC has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
BHC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.86 | 20% above |
| 20 week MA | $6.22 | 33% above |
| 50 week MA | $6.00 | 38% above |
| 100 week MA | $6.22 | 33% above |
| 200 week MA | $7.03 | 17% above |
BHC has climbed back above all five of its weekly moving averages, and it's now 17% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
BHC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.7 | $20.3 | -32% |
| 2021 | $20.3 | $28.0 | +38% |
| 2022 | $28.0 | $6.33 | -77% |
| 2023 | $6.33 | $8.02 | +27% |
| 2024 | $8.02 | $7.65 | -4.6% |
| 2025 | $7.65 | $7.20 | -5.9% |
| 2026 YTD | $7.20 | $8.25 | +15% |
BHC has finished lower in four of the last six years. It's up 15% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over BHC on returns for 2026, with the stronger performance.